ArriVent BioPharma, Inc. AVBP Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -55.2%— | -58.9%— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 14×-0.4× | 12.8×-0.3× | 14.9×-4.4× | 12.7×— | 14.3×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $7.19+20.3% | $7.99-2.4% | $7.28-11.9% | $7.14-19.4% | $5.97-52.9% | |
| Valuation | ||||||
| Market capitalization | $1.02B+62.1% | $830.58M-7.5% | $748.5M— | $790.65M— | $628.96M— | |
| Price / book | 3.1×0.0× | 2.7×-0.8× | 2.5×— | 3.2×— | 3.1×— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do ArriVent BioPharma, Inc.'s ratios come from?
- Every ratio is computed from ArriVent BioPharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.